Inovio tanks 40% after pausing coronavirus vaccine trial, trading halted | Markets

Steve Parsons-WPA Pool/Getty Images

• Inovio Pharmaceuticals tumbled as much as 39% on Monday after the biotech firm announced a temporary hold on its coronavirus vaccine’s phase 2/3 trial.Read More